-

DiaMedica Therapeutics to Participate in 11th Annual Craig-Hallum Alpha Select Conference

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for chronic kidney diseases and neurological disorders, today announced its President and CEO, Rick Pauls, and Chief Financial Officer, Scott Kellen, are scheduled to participate in the Craig-Hallum Alpha Select Conference, which is being held as a virtual event on November 17, 2020.

Meetings will take place virtually on November 17, 2020 given the ongoing call for social distancing due to the Covid-19 pandemic. Interested institutional investors should contact their Craig-Hallum sales representative to schedule a meeting.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders. DiaMedica’s shares are listed on The Nasdaq Capital Market under the trading symbol “DMAC.”

For more information, please visit www.diamedica.com.

Contacts

Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com

Industry:

DiaMedica Therapeutics Inc.

NASDAQ:DMAC
Release Versions
English

Contacts

Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com

More News From DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction and acute ischemic stroke (AIS), today provided a business update and reported financial results for the third quarter ended September 30, 2025. Management will host a conference call on Thursday, November 13, 2025, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update a...

DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that Rick Pauls, President and CEO, will participate in the Jefferies Global Healthcare Conference in London, taking place November 17-20, 2025. Mr. Pauls will deliver a corporate presentation and participate in one-on-one investor meetings during the confe...

DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its third quarter 2025 financial results will be released after the markets close on Wednesday, November 12th. DiaMedica will host a live conference call on Thursday, November 13th at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discuss financial...
Back to Newsroom